FDA approvedSexual healthGH axis

Gonadorelin

GnRH / Luteinizing Hormone-Releasing Hormone / Lutrepulse

FDA-approved GnRH analogue. Maintains testicular function and fertility during testosterone replacement therapy. Standard component of TRT protocols to prevent testicular atrophy.

Evidence

Phase III / FDA approved

Routes

injectable

Available since

FDA approved as Lutrepulse for infertility treatment. Category 1 compounding access well established.

Mechanism of action

Binds pituitary GnRH receptors to stimulate LH and FSH release. LH drives testicular testosterone production and sperm production. Used specifically to preserve HPG axis function during exogenous testosterone use which would otherwise suppress natural LH and FSH.

Effects in the body

Gonadorelin became a key peptide in TRT protocols after concerns about testicular atrophy from exogenous testosterone suppressing natural LH. It keeps the entire HPG axis active during testosterone therapy preserving both testicular size and fertility potential.

Pros & cons (from the literature)

Pros

FDA-approved — highest regulatory standing
Category 1 legal to compound
Preserves fertility and testicular function during TRT
Well characterized mechanism and safety data
Standard of care in responsible TRT protocols

Cautions

Very short half-life of 2-4 minutes requiring frequent dosing
Subcutaneous injection pump for optimal pulsatile use
Pulsatile administration is complex
Not a performance enhancing peptide — physiologic maintenance only

Protocol summary (from published research)

TRT protocol 100 mcg subcutaneous 2-3 times weekly to maintain LH and FSH pulsatility during testosterone therapy. Timing and frequency determined by physician based on lab monitoring.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

FDA-approved as Lutrepulse for infertility. Category 1 for compounding. Standard component of TRT protocols to maintain HPG axis function. One of the more straightforward regulatory situations.

Evidence base

Full FDA approval data from infertility indication. Decades of reproductive medicine use. Well characterized safety profile.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.